ライフサイエンスコーパス: phosphorothioate oligonucleotide

1 SI IRMPD FTICR mass spectrometry of a 20-mer phosphorothioate oligonucleotide.

2 stability of the TFO, we have used modified phosphorothioate oligonucleotides.

3 reated with CD44 sequence-specific antisense phosphorothioate oligonucleotides.

4 eversal potential between phosphodiester and phosphorothioate oligonucleotides.

5 plicable to the analysis and quantitation of phosphorothioate oligonucleotides.

6 s, and what was the effect of IL-6 antisense phosphorothioated oligonucleotides.

7 d by transfection with antisense PKC-epsilon phosphorothioate oligonucleotides (1,000 nM for 6 h).

8 The enzyme is inhibited by single-strand phosphorothioate oligonucleotides and displays no eviden

9 Down-regulation of PKCalpha by antisense phosphorothioate oligonucleotides and expression vectors

10 are relevant to both the therapeutic use of phosphorothioate oligonucleotides and the potential desi

11 d by 5' and 3' HNA sequences to conventional phosphorothioate oligonucleotides and to a 2'-O-methoxye

12 letion of DNA methyltransferase 1 (DNMT1) by phosphorothioate oligonucleotide antisense (DNMT1 AS) we

13 A 20-mer phosphorothioate oligonucleotide (AS1) was designed to h

14 ined whether the administration of antisense phosphorothioate oligonucleotides (ASOs) can mimic the l

15 A 20-mer phosphorothioate oligonucleotide capped with two phospho

16 mice with locked nucleic acid (LNA)-modified phosphorothioate oligonucleotide complementary to miR 14

17 myelogenous leukemia with OL(1)p53, a 20-mer phosphorothioate oligonucleotide complementary to p53 mR

18 suppression by G3139 (oblimersen sodium), a phosphorothioate oligonucleotide complementary to the bc

19 Retinal toxicity of ISIS 2922 and ISIS 4015, phosphorothioate oligonucleotides complementary to human

20 s well as cartilage slices were treated with phosphorothioate oligonucleotides comprised of sequence

21 t pulmonary endothelial cells given a 20-mer phosphorothioate oligonucleotide comprising an antisense

22 second strategy used isosequential "gap-mer" phosphorothioate oligonucleotides containing 2'-O-methyl

23 to increase stability, we have used modified phosphorothioate oligonucleotides for cell culture exper

24 Methods are presented for the extraction of phosphorothioate oligonucleotides from human plasma to p

25 Extraction of the phosphorothioate oligonucleotides from plasma was accomp

26 The phosphorothioate oligonucleotide 'gapmers', with 2'-O-DM

27 Phosphorothioate oligonucleotides have been demonstrated

28 d for their gene, mRNA, siRNA and 2'O-methyl phosphorothioate oligonucleotide in vitro transfection a

29 A MT antisense phosphorothioate oligonucleotide inhibited growth induct

30 we report that transfection of 2'-F-modified phosphorothioate oligonucleotides into cells can reduce

31 uptake of 15 different fluorescently labeled phosphorothioate oligonucleotides into human keratinocyt

32 ed HCV core protein levels as effectively as phosphorothioate oligonucleotide ISIS 6095 but without r

33 ve investigated the antiviral mechanism of a phosphorothioate oligonucleotide, ISIS 5652, which has a

34 wnregulation of IGF I receptors by antisense phosphorothioate oligonucleotides likewise markedly inhi

35 Triplex formation by the cyclin D1 targeted phosphorothioate oligonucleotide occurs with a binding a

36 Triplex formation with a modified phosphorothioate oligonucleotide occurs with approximate

37 gapmer was substantially more potent than a phosphorothioate oligonucleotide of the same sequence in

38 A phosphorothioate oligonucleotide, OL(1)p53, can be admin

39 antisense chimeric 2'-O-(2-methoxy)ethyl/DNA phosphorothioate oligonucleotides (ONs) to affect cell g

40 poteichoic acid (LTA), thymidine homopolymer phosphorothioate oligonucleotide [Poly(dT)], and polyino

41 on of RLIP76 using either siRNA or antisense phosphorothioate oligonucleotides preferentially caused

42 Phosphorothioate oligonucleotides (PS ODNs) prolong the

43 re systems were used to study the effects of phosphorothioate oligonucleotides (PS-ONs), as amphipath

44 Isis 3521 and G3139 are 20- and 18-mer phosphorothioate oligonucleotides, respectively, targete

45 vage as compared with the 7-mer C-5 propynyl phosphorothioate oligonucleotide (S-ON).

46 Phosphorothioate oligonucleotides (S-ODNs) or phosphorod

47 The antisense phosphorothioate oligonucleotides specific for IL-2, IL-

48 Proapoptotic phosphorothioate oligonucleotides such as G3139 (an 18-m

49 Here we have used specific phosphorothioate oligonucleotides targeted against the t

50 An antisense phosphorothioated oligonucleotide targeted to a unique s

51 inistration of ISIS 2302, a 20-mer antisense phosphorothioate oligonucleotide targeting human interce

52 imized C-5 propyne pyrimidine modified 7-mer phosphorothioate oligonucleotide targeting SV40 large T

53 A 20-mer phosphorothioate oligonucleotide targeting the 3'-untran

54 Fully modified 2'-O:-methoxy ethyl/phosphorothioate oligonucleotides that hybridize to the

55 this, we have synthesized a series of G-rich phosphorothioate oligonucleotides that inhibited activat

56 o test this hypothesis, we used an antisense phosphorothioate oligonucleotide to effect a 50% reducti

57 e demonstrate the ability of G3139 and other phosphorothioate oligonucleotides to bind directly to mi

58 or within the cell, the ability of antisense phosphorothioate oligonucleotides to inhibit the growth

59 important degradation pathway for antisense phosphorothioate oligonucleotides under conditions of th

60 s, and subsequently protein levels, by these phosphorothioate oligonucleotides was consistent with RN

61 Both phosphoramidate and phosphorothioate oligonucleotides were efficiently taken

62 , the combination of Ad.mda-7 with antisense phosphorothioate oligonucleotides, which target the K-ra

63 dy was to determine the abilities of various phosphorothioate oligonucleotides with cytosine-guanosin

64 Synthetic double-stranded phosphorothioate oligonucleotides with high affinity for